Market Performance: The Hang Seng Index (HSI) fell by 323 points (1.3%) to close at 25,201, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and HKEX saw significant drops, with Meituan down 3.1% and Tencent down 1.7%. Alibaba was an exception, gaining slightly by 0.2%.
Notable Movements: China Resources Mixc dropped sharply by 9.1%, while Nongfu Spring rose by 7.1%, reaching a new high. Other notable losers included CSPC Pharma and Hansoh Pharma.
Short Selling Activity: High short selling ratios were observed across various stocks, indicating increased bearish sentiment in the market, particularly for companies like Kuaishou and China Life.
Wall Street analysts forecast 00241 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00241 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 00241 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00241 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 7.780
Low
Averages
High
Current: 7.780
Low
Averages
High
CLSA
CLSA
Outperform
maintain
Al Analysis
2025-12-08
Reason
CLSA
CLSA
Price Target
Al Analysis
2025-12-08
maintain
Outperform
Reason
The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.
JPMorgan
JPMorgan
Neutral
maintain
$6.5
2025-12-03
Reason
JPMorgan
JPMorgan
Price Target
$6.5
2025-12-03
maintain
Neutral
Reason
The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 00241
Unlock Now
Goldman Sachs
Goldman Sachs
Neutral
maintain
2025-12-02
Reason
Goldman Sachs
Goldman Sachs
Price Target
2025-12-02
maintain
Neutral
Reason
Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.
UBS
downgrade
2025-12-02
Reason
UBS
Price Target
2025-12-02
downgrade
Reason
The analyst rating from UBS was downgraded due to a belief that the performance of ALI HEALTH was primarily driven by a structural shift from offline to online pharmaceutical supply, rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. Despite the company's first-party platform sales growth surpassing forecasts, UBS maintains a cautious outlook, suggesting that leading peers may benefit more from this structural trend. Consequently, while the target price was raised, the Sell rating remained in place.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
